PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 60.24

Change

+0.52 (+0.87)%

Market Cap

N/A

Volume

3.72K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-23 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.67 (+0.50%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+0.40 (+0.63%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+1.17 (+1.22%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

+1.58 (+2.09%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.27 (+1.35%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

+1.73 (+1.88%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.45 (+1.63%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.60 (+2.35%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.88 (+1.60%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.36 (+2.01%)

USD 0.01B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.45% 29% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.45% 29% F 30% F
Trailing 12 Months  
Capital Gain -1.05% 67% D+ 45% F
Dividend Return 0.01% 6% D- N/A F
Total Return -1.04% 67% D+ 36% F
Trailing 5 Years  
Capital Gain 12.47% 43% F 39% F
Dividend Return 0.09% 5% F N/A F
Total Return 12.55% 43% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 2.53% 48% F 46% F
Dividend Return 2.55% 48% F 36% F
Total Return 0.02% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 16.95% 52% F 59% D-
Risk Adjusted Return 15.03% 52% F 33% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.